Polyamino-polycarbonyl Moiety Attached To Or Complexed With The Metal Patents (Class 424/9.364)
  • Patent number: 11052164
    Abstract: The present disclosure relates to polymeric materials that may be labeled with a radioisotope, to processes for producing the labeled polymeric material, and to methods of using the materials in analytical and therapeutic applications. Specifically, the disclosure relates to injectable and implantable microparticles, such as microspheres, which are associated with radioisotopes such that the microparticles are both therapeutic and detectable. The radioisotope-containing microparticles are useful for embolization and other therapeutic medical applications.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: July 6, 2021
    Assignee: Biosphere Medical, Inc.
    Inventors: Philippe Reb, Celine Chaix
  • Patent number: 10891260
    Abstract: Methods and systems are disclosed for analyzing equipment data, determining an occurrence of an event, and transmitting a message based on the event.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: January 12, 2021
    Assignee: RMC PHARMACEUTICAL SOLUTIONS, INC.
    Inventors: Scott Rudge, Korben Knudson
  • Patent number: 10809339
    Abstract: Methods and systems for performing magnetic resonance diffusion weighted imaging of an object is provided. The method includes applying a plurality of diffusion gradients to a plurality of image slices of the object during a plurality of repetition times via an MRI system. A different diffusion gradient of the plurality is applied to each image slice during the same repetition time.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: October 20, 2020
    Assignee: GE PRECISION HEALTHCARE LLC
    Inventors: Ke Li, Gaohong Wu, Eric Printz, Kenichi Kanda, Margaret Ann Wiza
  • Patent number: 10353868
    Abstract: Methods and systems are disclosed for analyzing equipment data, determining an occurrence of an event, and transmitting a message based on the event.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: July 16, 2019
    Assignee: RMC PHARMACEUTICAL SOLUTIONS, INC.
    Inventors: Scott Rudge, Korben Knudson
  • Patent number: 9687573
    Abstract: The present disclosure relates to polymeric materials that may be labeled with a radioisotope, to processes for producing the labeled polymeric material, and to methods of using the materials in analytical and therapeutic applications. Specifically, the disclosure relates to injectable and implantable microparticles, such as microspheres, which are associated with radioisotopes such that the microparticles are both therapeutic and detectable. The radioisotope-containing microparticles are useful for embolization and other therapeutic medical applications.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 27, 2017
    Assignee: Biosphere Medical, Inc.
    Inventors: Philippe Reb, Celine Chaix
  • Patent number: 9417230
    Abstract: The disclosure provides a method for quantification of hepatic function in a subject comprising measuring the clearance of an orally administered isotopically labeled cholic acid in a subject with, or suspected of having or developing, a hepatic disorder, for example, chronic hepatitis C. The disclosure further provides methods and kits for assessment of hepatic function.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: August 16, 2016
    Assignee: The Regents of the University of Colorado, a Body Corporate
    Inventor: Gregory Thomas Everson
  • Patent number: 9034298
    Abstract: Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with 5 the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T 1/T 2 weighted contrast agents or CEST contrast agents) SPECT, PET or Spectral CT.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: May 19, 2015
    Assignee: Koninklijke Philips N.V.
    Inventors: Holger Gruell, Anke De Vries, Sander Langereis, Johan Lub, Erica M. G. Aussems-Custers
  • Patent number: 8961949
    Abstract: The present invention provides a polymer-metal complex composite, which comprises a block copolymer capable of serving as a constituent member of a polymeric micelle and a metal complex having MRI contrast ability, accumulates in a tumor-specific manner, achieves high image contrast even in a small amount, and has reduced side effects and a long retention time in blood. The polymer-metal complex composite of the present invention comprises a block copolymer (A) represented by general formula (a) and a metal complex (B) having MRI contrast ability, wherein the composite comprises a structure in which a carboxyl anion of poly(carbo) in the copolymer (A) is attached to the metal complex (B) via a metal atom (M).
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: February 24, 2015
    Assignee: Japan Science and Technology Agency
    Inventors: Kazunori Kataoka, Sachiko Kaida, Horacio Cabral, Michiaki Kumagai, Masaki Sekino
  • Patent number: 8911710
    Abstract: Intravascular contrast agents are provided by Gd-chelates modified so as to comprise an amino acid unit attached to the chelate via a linker group suitably selected from C2-4alkylene and C3-5alkynylene. The chelates may be used as an intravascular contrast agent for MRI. Certain embodiments demonstrate enhanced relaxivity and good levels of signal enhancement.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: December 16, 2014
    Assignees: Agency for Science, Technology and Research, Nanyang Technological University
    Inventors: Roderick Wayland Bates, Xavier Golay, Changtong Yang
  • Patent number: 8877163
    Abstract: A cycloalkyl triamine pentacarboxylate compound coordinating to a metal ion to form a high stability metal complex in serum is provided. The metal complex of the present invention can be used as a contrast agent for magnetic resonance imaging (MRI).
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: November 4, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Yun-Ming Wang, Chih-Wei Chiu, Gin-Chung Liu
  • Patent number: 8703097
    Abstract: Provided are signal modifying compositions for medical imaging comprising a carrier and two or more signal modifying agents specific for two or more imaging modalities. The compositions are characterized by retention efficiency, with respect to the signal modifying agents, which enables prolonged contrast imaging without significant depletion of the signal modifying agents from the carrier. The carriers of the present invention are lipid based or polymer based, the physico-chemical properties of which can be modified to entrap or chelate different signal modifying agents and mixtures thereof and to target specific organs or tumors or tissues within a mammal.
    Type: Grant
    Filed: February 10, 2006
    Date of Patent: April 22, 2014
    Assignee: University Health Network
    Inventors: David Jaffray, Christine Allen, Jinzi Zheng, Raymond Matthew Reilly, Gregory Jason Perkins
  • Publication number: 20140105829
    Abstract: A novel nanoemulsion formulation useful for the delivery of docetaxel chemotherapeutic agents is provided, as well as methods of their preparation and use in cancer patients and for cancer imaging.
    Type: Application
    Filed: October 15, 2013
    Publication date: April 17, 2014
    Applicant: Nemucore Medical Innovations, Inc.
    Inventors: Srinivas Ganta, Timothy P. Coleman
  • Patent number: 8562953
    Abstract: A dendritic polymer and a magnetic resonance imaging contrast agent employing the same. The magnetic resonance contrast agent includes the dendritic polymer according to the structure of SP-DZ-L)i)j or SP-DX-Z-L)i)j, wherein, S is cyclosilane moiety with j silicon oxygen residual groups, and j is not less than 2; P is CH2CH2Ol, and l is not less than 1; D is a C3-30 dendritic moiety having n oxygen residue, and n is not less than 3; X is C3-30 moiety having bi-functional groups; Z is a C3-20 moiety having a plurality of functional group; and L is a metal cation.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: October 22, 2013
    Assignee: Industrial Technology Research Institute
    Inventors: Dhakshanamurthy Thirumalai, Chin-I Lin, Shian-Jy Wang
  • Publication number: 20130224113
    Abstract: The present invention relates to the use of a combination of several contrast agents having different properties with respect to imaging representation.
    Type: Application
    Filed: April 11, 2013
    Publication date: August 29, 2013
    Applicant: MIVENION GMBH
    Inventor: MIVENION GMBH
  • Patent number: 8404216
    Abstract: The invention relates to dendritic chelated compounds, to methods for producing the same and to pharmaceutical compositions containing the same. The dendritic chelated complexes of the present invention have the following formula (I): [[MC]En-[D]m-X1p1X2p2X3p3X4p4]z?zB+ (I), where m is a magnetic or scintigraphic marker, C is a chelating agent of the marker M, E is a spacer, n=0 or 1, D is compound capable of forming a dendritic structure, m is an integer equal to 1 or 2 or 4, X1 is a group increasing the complex lipophily, p1 is an integer from 0 to 12, X2 is a group increasing the complex specificity for a particular organ, p2 is an integer equal to 1 or 2 or 4, X3 is a group having a therapeutic activity, p3 is an integer equal to 0, 1, 2 or 4, X4 is a CH3 group, p4 is an integer from 0 to 12, B is a counter-ion, z is an integer equal to 0, 1, 2, 3 or 4. The invention can be used in the field of pharmacy, more precisely in medical imaging.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: March 26, 2013
    Assignees: Centre National de la Recherche Scientifique, Universite Louis Pasteur
    Inventors: Delphine Felder-Flesch, Jérôme Steibel, Annabelle Bertin
  • Patent number: 8394356
    Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: March 12, 2013
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
  • Patent number: 8323621
    Abstract: Cyclen-based chelates can be used as contrast agents for multi-modal imaging of tissue cells. The cyclen-based chelates are preferably polyazamacrocyclic molecules formed from 1,4,7,10 tetraazacyclododecane (“cyclen”) having varying chelating ions, phosphoester chains, and light harvesting moieties. By changing the chelating ion, phosphoester chain length and/or the light harvesting moiety different imaging techniques, such as MRI, CT, fluorescence and absorption, x-ray and NIR, may be employed to image the tissue cells. Additionally, the cyclen-based chelates may be conjugated to provide for site-specific delivery of the cyclen-based chelate to the desired tissue cells. The cyclen-based chelates may also be delivered to the tissue cells by attaching the cyclen-based to a polymeric delivery vehicle. Although these cyclen-based chelates have a wide variety of application, the preferred use is for imaging of cancer cells, such as brain cancer, for improving resection of a cancerous tissue.
    Type: Grant
    Filed: March 4, 2008
    Date of Patent: December 4, 2012
    Assignees: Vanderbilt University, Texas Tech University System
    Inventors: Darryl J. Bornhop, H. Charles Manning, Timothy Goebel
  • Patent number: 8303937
    Abstract: A dendritic polymer and a magnetic resonance imaging contrast agent employing the same. The magnetic resonance contrast agent includes the dendritic polymer according to the structure of SP-DZ-L)i)j or SP-DX-Z-L)i)j, wherein, S is cyclosilane moiety with j silicon oxygen residual groups, and j is not less than 2; P is and l is not less than 1; D is a C3-30 dendritic moiety having n oxygen residue, and n is not less than 3; X is C3-30 moiety having bi-functional groups; Z is a C3-20 moiety having a plurality of functional group; and L is a metal cation.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: November 6, 2012
    Assignee: Industrial Technology Research Institute
    Inventors: Dhakshanamurthy Thirumalai, Chin-I Lin, Shian-Jy Wang
  • Publication number: 20120121517
    Abstract: The present invention relates to a poly(organophosphazene)-superparamagnetic nanoparticle complex including a biodegradable and thermosensitive poly(organophosphazene) and a iron oxide (Fe3O4, Magnetite)-series ferrite superparamagnetic nanoparticle, a preparation method, and uses of carrying a physiologically-active material, a bio-material and a biomaterial for cancer hyperthermia. The iron oxide is used as a MRI contrast agent for T-2 and T2* weighted image, and the poly(organophosphazene) shows a sol-to-gel behavior depending upon the temperature change. The complex is a bound-type where the superparamagnetic ferrite nanoparticle is bonded to phosphazene-based polymer via hydrophobic binding, and a mixed-type where the superparamagnetic ferrite nanoparticle is physically mixed with the phosphazene-based polymer.
    Type: Application
    Filed: June 30, 2011
    Publication date: May 17, 2012
    Inventors: Soo-Chang SONG, Jang Il KIM
  • Publication number: 20120107249
    Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
    Type: Application
    Filed: August 29, 2011
    Publication date: May 3, 2012
    Applicant: LANTHEUS MEDICAL IMAGING, INC.
    Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
  • Publication number: 20120087869
    Abstract: Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.
    Type: Application
    Filed: October 6, 2011
    Publication date: April 12, 2012
    Applicant: MEDTRONIC, INC.
    Inventors: Deepak Ramesh Thakker, Lisa L. Shafer, Greg Stewart
  • Publication number: 20120020876
    Abstract: This disclosure generally relates to methods useful for improving, for example, blood vessel density and/or blood vessel patency to a tissue by administration of a hedgehog pathway inhibitor. In certain embodiments, the hedgehog pathway inhibitor is administered with an agent to improve the delivery of the agent to the tissue. In certain embodiments, the tissue comprises tumor tissue.
    Type: Application
    Filed: January 22, 2010
    Publication date: January 26, 2012
    Inventors: Kenneth Paul Olive, David Tuveson
  • Patent number: 8092782
    Abstract: The invention relates generally to biotin-containing compounds that are useful as imaging agents and drug-delivery agents. Another aspect of the invention relates to the aforementioned compounds chelated to a metal atom. In a preferred embodiment, the metal atom is a gadolinium. Another aspect of the invention relates to a compound comprising three biotin moieties and a pharmaceutical agent covalently bound to a heterocyclic core. In certain embodiments, the pharmaceutical agent is an antibiotic, antiviral, or radionuclide. Another aspect of the present invention relates to a method of treating disease involving administering the compounds of the invention to a mammal. Another aspect of the present invention relates to a method of acquiring a magnetic resonance image using the compounds of the invention.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: January 10, 2012
    Assignee: The General Hospital Corporation
    Inventors: David R. Elmaleh, Timothy M. Shoup, Alan J. Fischman
  • Patent number: 8017105
    Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
    Type: Grant
    Filed: June 22, 2006
    Date of Patent: September 13, 2011
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
  • Publication number: 20110177009
    Abstract: Described are drug carriers useful in magnetic resonance imaging (MRI)-guided drug release comprising a shell capable of releasing an enclosed biologically active agent as a result of a local stimulus, e.g. energy input, such as heat, wherein the shell encloses a 19F MR contrast agent. Preferably, the carrier also acts as a contrast enhancement agent for MRI based on the principle of Chemical Exchange-dependent Saturation Transfer (CEST). To this end the shell encloses a cavity that comprises a paramagnetic chemical shift reagent, a pool of proton analytes, and the 19F contrast agent, and wherein the shell allows diffusion of the proton analytes.
    Type: Application
    Filed: September 3, 2009
    Publication date: July 21, 2011
    Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.
    Inventors: Sander Langereis, Jochen Keupp, Holger Gruell, Dirk Burdinski, Danielle Beelen
  • Patent number: 7947253
    Abstract: The present invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, such as cells undergoing apoptosis or activated platelets. The invention further provides methods for utilizing said compounds in medical practice, for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: January 16, 2005
    Date of Patent: May 24, 2011
    Assignee: Aposense Ltd.
    Inventors: Ilan Ziv, Anat Shirvan
  • Publication number: 20110076237
    Abstract: In one aspect, the present invention provides a contrast enhancement agent comprising an iron chelate having structure I wherein R1 is independently at each occurrence a hydroxy group, a C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group, and b is 0-4; R2-R7 are independently at each occurrence hydrogen, a C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group, with the proviso that at least one of R1-R7 is a hydroxy group or a C1-C3 hydroxyalkyl group; and wherein Q is a charge balancing counterion. Also provided is a metal chelating ligand having structure IX and medical formulations comprising the contrast enhancement I.
    Type: Application
    Filed: September 30, 2009
    Publication date: March 31, 2011
    Applicant: GENERAL ELECTRIC COMPANY
    Inventors: Brian James Grimmond, Michael Todd Luttrell, Jeannette Christine DePuy, Mary Elizabeth Spilker, Michael James Rishel
  • Patent number: 7917188
    Abstract: A method for mapping a physico-chemical parameter using a chemical exchange saturation transfer contrast agent in Magnetic Resonance Imaging is used with agents having only one exchangeable entity pool, e.g. proton pool, by applying two different RF frequencies for pre-saturation of the contrast agent.
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: March 29, 2011
    Assignee: Koninklijke Philips Electronics N.V.
    Inventors: Rene Theodorus Wegh, Jeroen Alphons Pikkemaat, Nicolaas Petrus Willard
  • Patent number: 7897140
    Abstract: Novel tetrapyrollic water soluble photosensitizing and imaging compounds and the methods of treating and imaging hyperproliferative tissue, e.g. tumors and hypervacularized tissue such as found in macular degeneration. Broadly, the compounds are tetrapyrollic photosensitizer compounds where the tetrapyrollic compound is a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide having 3 to 6 —CH2CONHphenylCH2CH(N(CH2COOH)2))(CH2N(CH2COOH)(CH2CH2N(CH2COOH)2)) groups or esters thereof or complexes thereof with gadolinium(III).
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: March 1, 2011
    Assignee: Health Research, Inc.
    Inventors: Ravindra K. Pandey, Lalit Goswami, Joseph Spernyak, Peter Kanter, Richard Mazurchuk
  • Patent number: 7767196
    Abstract: An adamantane functionalized magnetic resonance imaging (MRI) contrast agent has been synthesized, and shows high liver specificity, prolonged retention time in both the liver and kidneys, the highest relaxivity among clinical contrast agents, high water solubility, thermodynamic stability, signal intensity enhancement, hepatocellular uptake, and low osmolality and toxicity.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: August 3, 2010
    Assignee: The University of Hong Kong
    Inventors: Wing Tak Wong, Wai Yan Chan
  • Patent number: 7727512
    Abstract: Compounds useful for associating with nanoparticle or microparticle emulsions to obtain magnetic resonance images permit control of the relaxivity of the signal and readily associate with the particulate components.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: June 1, 2010
    Assignees: Barnes-Jewish Hospital, The Dow Chemical Company
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Phillip S. Athey, Gyongyi Gulyas, Garry E. Kiefer
  • Patent number: 7670590
    Abstract: The present invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, such as cells undergoing apoptosis or activated platelets. The invention further provides methods for utilizing said compounds in medical practice, for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: March 2, 2010
    Assignee: Aposense Ltd.
    Inventors: Ilan Ziv, Anat Shirvan
  • Patent number: 7666390
    Abstract: The present invention relates to diethylenetriamine pentaacetic acid (DTPA) derivates and metal complexes thereof, and radiation sources and contrast agents including the metal complexes. More particularly, the present invention relates to DTPA derivatives, which contain iodine and are useful as contrast agents for diagnosing renal function, metal complexes of the DTPA derivatives with 99mTc, 166Ho, 111In, 90Y, 153Sm, 186Re, 188Re, 68Ga, or 177Lu, which are useful as liquid radiation sources for treating vascular stenosis and contrast agents for diagnosing renal function, and radiation sources and contrast agents including the metal complexes. The DTPA derivatives and metal complexes thereof are safe because the metal complexes are excreted via the kidneys and bladder within several minutes from the time of use as liquid radiation sources for treating vascular stenosis, and are cost-effective because they are potentially useful as contrast agents and as agents for diagnosing renal function.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: February 23, 2010
    Assignee: Korea Atomic Energy Research Institute
    Inventors: Young-Don Hong, Sun-Ju Choi, Ok Ja Choi
  • Patent number: 7608249
    Abstract: The invention relates to a method for the Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy Imaging of a substrate molecule different from water wherein the NMR signal is enhanced by a reversible binding of the substrate molecule to a paramagnetic chelate complex, as well as to the use of a paramagnetic chelate complex in said method and the pharmaceutical composition for use therein.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: October 27, 2009
    Assignee: Bracco Imaging S.p.A.
    Inventors: Enzo Terreno, Silvio Aime, Mauro Botta
  • Publication number: 20090208422
    Abstract: Method and composition suitable for administering by direct convective interstitial infusion are disclosed. The method comprises: placing at least one direct convective interstitial infusion catheter in contact with the tissue, and pressuring the composition through the catheter. The composition is in a liquefied form having a viscosity above a predetermined value. The predetermined value is selected so as to improve infusion of the compositions into interstitial volumes of the tissue, while minimizing backflow of the compositions along an outer wall of the catheter or leakage into low resistance paths. It is demonstrated that high viscosity results in higher treatment efficiency.
    Type: Application
    Filed: September 29, 2005
    Publication date: August 20, 2009
    Applicants: Medical Research Fund of Tel Aviv, Tel HaShomer Medical research Infrastructure and Service Ltd
    Inventors: Yael Mardor, Zvi Ram
  • Patent number: 7557577
    Abstract: The invention relates to the use of a water-soluble paramagnetic substance, in particular a magnetic resonance contrast medium, to reduce the magnetic resonance relaxation time of a coolant for magnetic resonance systems. Furthermore the invention relates to a corresponding method for reducing the magnetic resonance relaxation time of a coolant.
    Type: Grant
    Filed: December 8, 2004
    Date of Patent: July 7, 2009
    Assignee: Siemens Aktiengesselschaft
    Inventors: Norbert Gläsel, Ulrich Nerreter
  • Publication number: 20090087377
    Abstract: The present invention relates to the field of radiochemistry, nuclear imaging, radionuclide therapy and chemical synthesis. More particularly, it concerns a strategy for radiolabeling target ligands. It further concerns methods of using those radiolabeled ligands for imaging, radionuclide therapy and tissue-specific disease imaging.
    Type: Application
    Filed: March 27, 2008
    Publication date: April 2, 2009
    Inventors: Ali Azhdarinia, Ebrahim S. Delpassand, Izabela Tworowska, Jennifer Sims-Mourtada
  • Patent number: 7438893
    Abstract: The invention relates generally to biotin-containing compounds that are useful as imaging agents and drug-delivery agents. Another aspect of the invention relates to the aforementioned compounds chelated to a metal atom. In a preferred embodiment, the metal atom is a gadolinium. Another aspect of the invention relates to a compound comprising three biotin moieties and a pharmaceutical agent covalently bound to a heterocyclic core. In certain embodiments, the pharmaceutical agent is an antibiotic, antiviral, or radionuclide. Another aspect of the present invention relates to a method of treating disease involving administering the compounds of the invention to a mammal. Another aspect of the present invention relates to a method of acquiring a magnetic resonance image using the compounds of the invention.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: October 21, 2008
    Assignee: Massachusetts General Hospital
    Inventors: David R. Elmaleh, Timothy Shoup, Alan J. Fischman
  • Publication number: 20080044360
    Abstract: Diagnostic compositions and methods for imaging and/or assessing collagen are described. The diagnostic compositions can include collagen binding peptides.
    Type: Application
    Filed: December 29, 2006
    Publication date: February 21, 2008
    Inventors: Peter Caravan, Andrew Kolodziej, Zhaoda Zhang, Stephane Dumas, Biplab Das, Vincent Jacques, Richard Looby, Steffi Koerner, Wei-Chuan Sun, David Buckler, Aida Abujoub, Aaron Sato
  • Publication number: 20070269384
    Abstract: The invention relates to the use of metal complexes that contain at least one perfluorinated alkyl radical and at least one chelating agent radical and at least one metal ion equivalent of the atomic numbers 21-29, 31-33, 37-39, 42-44, 49 or 57-83, as well as salts thereof for the production of a diagnostic agent for visualizing amyloid-containing plaques.
    Type: Application
    Filed: May 8, 2007
    Publication date: November 22, 2007
    Inventors: Bernd Misselwitz, Hanns-Joachim Weinmann, Joerg Meding
  • Patent number: 7279150
    Abstract: Compounds useful for associating with nanoparticle or microparticle emulsions to obtain magnetic resonance images permit control of the relaxivity of the signal and readily associate with the particulate components.
    Type: Grant
    Filed: January 26, 2004
    Date of Patent: October 9, 2007
    Assignees: Barnes-Jewish Hospital, The Dow Chemical Corporation
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Phillip S. Athey, Gyongyi Gulyas, Garry E. Kiefer
  • Patent number: 7270799
    Abstract: The present invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, such as cells undergoing apoptosis or activated platelets. The invention further provides methods for utilizing said compounds in medical practice, for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: March 15, 2004
    Date of Patent: September 18, 2007
    Assignee: NST NeuroSurvival Technologies Ltd.
    Inventors: Ilan Ziv, Anat Shirvan
  • Publication number: 20070207087
    Abstract: A cycloalkyl triamine pentacarboxylate compound coordinating to a metal ion to form a high stability metal complex in serum is provided. The metal complex of the present invention can be used as a contrast agent for magnetic resonance imaging (MRI).
    Type: Application
    Filed: September 21, 2006
    Publication date: September 6, 2007
    Applicant: Kaohsiung Medical University
    Inventors: Yun-Ming Wang, Chih-Wei Chiu, Gin-Chung Liu
  • Patent number: 7229606
    Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
    Type: Grant
    Filed: January 12, 2004
    Date of Patent: June 12, 2007
    Assignee: Epix Pharmaceuticals, Inc.
    Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
  • Publication number: 20070128119
    Abstract: The disclosure provides pendant fatty acid compounds for use in diagnostic imaging, (particularly the cardiovascular system), as well as kits comprised of the same. The disclosure also provides for a method administering a imaging agent with a high specificity for the myocardium.
    Type: Application
    Filed: November 13, 2006
    Publication date: June 7, 2007
    Inventor: John Babich
  • Patent number: 7211241
    Abstract: Described are new cascade polymer complexes, compositions containing them and use of the complexes in diagnosis and therapy, particularly for magnetic resonance imaging and computer tomography imaging.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: May 1, 2007
    Assignee: Schering Aktiengesellschaft
    Inventors: Heribert Schmitt-Willich, Johannes Platzek, Bernd Radüchel, Andreas Mühler, Thomas Frenzel
  • Patent number: 7208139
    Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21–29, 39, 42, 44 or 57–83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: April 24, 2007
    Assignee: Schering AG
    Inventors: Johannes Platzek, Heribert Schmitt-Willich, Heinz Gries, Gabriele Schuhmann-Giampieri, Hubert Vogler, Hanns-Joachim Weinmann, Hans Bauer
  • Patent number: 7198776
    Abstract: The invention relates to metal complex compounds, contrast agents for MRI and in vivo NMR markers for NMR spectroscopy comprising said metal complex compounds and methods for in vivo determination of physiological parameters, e.g. enzyme activity or pH using said metal complex compounds.
    Type: Grant
    Filed: November 28, 2002
    Date of Patent: April 3, 2007
    Assignee: GE Healthcare AS
    Inventors: Jo Klaveness, Pal Rongved
  • Patent number: 7175829
    Abstract: The present invention relates to a contrast-enhanced diagnostic imaging method for monitoring the efficacy of interventional therapies. The contrast agents useful in this method comprise an image-enhancing moiety (IEM) and a state-dependent tissue binding moiety (SDTBM). These contrast agents exhibit state-dependent binding to one or more components of a targeted tissue or tissue component and provide a detectable change in the signal characteristics of the agent once bound to the targeted tissue. As a result, these agents exhibit a binding affinity for, and thus image contrast of, the targeted tissue which changes as the tissue-state changes during therapy.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: February 13, 2007
    Assignee: Epix Pharmaceuticals, Inc.
    Inventors: Randall B. Lauffer, Stephen O. Dunham
  • Publication number: 20070020176
    Abstract: The present invention relates to a contrast agent of Formula I V-L-Z Formula I where V is a non-peptidic vector having affinity for the Angiotensin II receptor, L is a bond, a spacer or a linker moiety and Z represents a moiety detectable in an in vivo imaging procedure of a human or animal body.
    Type: Application
    Filed: January 9, 2004
    Publication date: January 25, 2007
    Inventors: Magne Solbakken, Torgrim Engell, Harry Wadsworth, Colin Archer